- Home
- ORIC vs ITOS Comparison
ORIC vs ITOS Comparison
Compare ORIC & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORIC
- ITOS
- Stock Information
- Founded
- ORIC 2014
- ITOS 2011
- Country
- ORIC United States
- ITOS United States
- Employees
- ORIC N/A
- ITOS N/A
- Industry
- ORIC Biotechnology: Pharmaceutical Preparations
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ORIC Health Care
- ITOS Health Care
- Exchange
- ORIC Nasdaq
- ITOS Nasdaq
- Market Cap
- ORIC 362.9M
- ITOS 381.2M
- IPO Year
- ORIC 2020
- ITOS 2020
- Fundamental
- Price
- ORIC $11.10
- ITOS $10.26
- Analyst Decision
- ORIC Strong Buy
- ITOS Hold
- Analyst Count
- ORIC 9
- ITOS 6
- Target Price
- ORIC $18.29
- ITOS $10.60
- AVG Volume (30 Days)
- ORIC 949.2K
- ITOS 764.9K
- Earning Date
- ORIC 08-11-2025
- ITOS 08-07-2025
- Dividend Yield
- ORIC N/A
- ITOS N/A
- EPS Growth
- ORIC N/A
- ITOS N/A
- EPS
- ORIC N/A
- ITOS N/A
- Revenue
- ORIC N/A
- ITOS $35,000,000.00
- Revenue This Year
- ORIC N/A
- ITOS N/A
- Revenue Next Year
- ORIC N/A
- ITOS N/A
- P/E Ratio
- ORIC N/A
- ITOS N/A
- Revenue Growth
- ORIC N/A
- ITOS 177.89
- 52 Week Low
- ORIC $3.90
- ITOS $4.80
- 52 Week High
- ORIC $14.67
- ITOS $18.13
- Technical
- Relative Strength Index (RSI)
- ORIC 66.82
- ITOS 66.97
- Support Level
- ORIC $10.42
- ITOS $10.05
- Resistance Level
- ORIC $11.50
- ITOS $10.21
- Average True Range (ATR)
- ORIC 0.62
- ITOS 0.13
- MACD
- ORIC -0.03
- ITOS -0.06
- Stochastic Oscillator
- ORIC 83.30
- ITOS 81.48
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.